Caution and pharma’s AI adoption: understanding the reasons behind uneven uptake

AI adoption across pharma commercial teams remains uneven, even as AI piloting expands. Nicole Ventrone, Partner at Beghou, and Brett Ramos, Sr. Director of Commercial Operations and Analytics at Neurelis, share findings from a study of 100 biopharma commercial leaders, showing that adoption varies within teams and is shaped more by practical use cases than by job role or age.

The study identifies compliance and regulatory uncertainty as the leading barrier, followed by data quality, insufficient training, and a lack of approved use cases. Read the article that explains how evaluating one use case at a time, with clear guardrails and governance, can help organizations address those concerns and make progress without waiting for a company-wide rollout.